Prof George Baillie and his research team publish their recent review in Nature Reviews in Drug Discovery

Congratulations to the Baillie Group for its recent Review in Nature Reviews in Drug Discovery. The prestigious review is commissioned every 4 years by Nature and covers the most influential and topical advances in the field of cyclic-nucleotide signalling.

The current review summarises latest therapeutic applications of PDE inhibitors while focussing on novel approaches such as using PDE signatures as biomarkers, altered compartmentalisation as an alternative to global inhibition and the intramolecular mechanisms that regulate PDE function

Read Therapeutic targeting of 3′,5′-cyclic nucleotide phosphodiesterases: inhibition and beyond

 George Baillie Nature Review story image


First published: 21 October 2019